Strengthening Global Psoriasis Care Initiatives
The International Federation of Psoriasis Associations (IFPA) and the WHO Foundation have entered into a crucial partnership aimed at enhancing care for psoriasis, a chronic noncommunicable disease affecting over 100 million individuals globally. This collaboration is designed to bolster the understanding, diagnosis, and overall management of psoriasis across the world.
Challenges Surrounding Psoriasis
Psoriasis is more than just a skin condition; it significantly impacts individuals physically, emotionally, and financially. Those affected may also encounter various other health issues, including depression and cardiovascular diseases. Despite affecting such a large population, psoriasis often goes misunderstood and overlooked in healthcare discussions.
The Need for Accurate Data
Currently, only approximately 20 percent of countries have adequate epidemiological data on psoriasis, as noted by the Global Psoriasis Atlas. This lack of essential information leads to delayed diagnosis, unequal access to proper care, and a failure to recognize psoriasis as a chronic condition that affects multiple life aspects.
Milestone Collaboration Agreement
The recent agreement between IFPA and the WHO Foundation marks a significant step toward addressing these challenges. This multi-year partnership will not only focus on increasing knowledge and strengthening evidence but also aims to improve health policies related to psoriasis and ensure better access to care globally.
Voices from the Leadership
Frida Dunger, the Executive Director of IFPA, expressed the importance of this collaboration by stating, "Signing this agreement with the WHO Foundation is a pivotal moment for IFPA and the entire global psoriasis community. We are excited to combine our efforts to make a profound impact for those living with psoriasis. Many, particularly in developing regions, are still without proper diagnoses or treatment access, suffering from stigma and mental health challenges."
Similarly, Anil Soni, Chief Executive Officer of the WHO Foundation, highlighted the connection between skin health and broader health issues. He stated, "Psoriasis illustrates how skin health connects to broader noncommunicable diseases, mental health, and access to care. Our collaboration with IFPA will focus on mobilizing support for WHO-led initiatives and improving access to care. Better data will empower countries to make informed health policy decisions and drive progress towards universal health coverage."
Key Areas of Focus
The agreement between IFPA and the WHO Foundation aims to build on earlier resolutions and reports that have brought psoriasis into global health conversations. The intention is to update the Global Report on Psoriasis, reflecting the latest prevalence data and treatment advancements. Since the last report in 2016, new research has unveiled the systemic nature of psoriasis and its connection to other serious health conditions, highlighting the need for an urgent update.
Future Collaborative Goals
The collaboration will concentrate on key priorities, including:
- Sharing evidence-based recommendations and guidance with global health authorities.
- Developing diagnostic tools that utilize AI for early and accurate detection, especially in resource-limited settings.
- Training healthcare professionals to improve their ability to recognize and manage psoriasis effectively.
In addition, this partnership aims to bring psoriasis into broader discussions surrounding chronic diseases and mental health, ensuring that individuals living with this condition are recognized and supported.
About IFPA
Founded in 1971 and located in Stockholm, Sweden, the International Federation of Psoriasis Associations (IFPA) is committed to advocating for all those affected by psoriatic diseases. Including members from national and regional patient associations, IFPA represents over 60 million people worldwide. Their initiatives such as the World Psoriasis Day campaigns and the IFPA Forum aim to redefine psoriatic disease as a critical focus for inclusive health systems globally.
About WHO Foundation
The WHO Foundation is an independent organization established in 2020 to support the mission of the World Health Organization, based in Geneva, Switzerland. Its efforts center on mobilizing philanthropic resources and cultivating partnerships that enhance health equity, respond to urgent health issues, and strengthen life-saving systems. By translating innovative solutions into real-world applications, the Foundation is actively driving lasting changes toward achieving health for all.
Frequently Asked Questions
What is psoriasis?
Psoriasis is a chronic skin condition that can significantly impact overall health, leading to various physical and mental health issues.
Why is the IFPA and WHO Foundation collaboration important?
This collaboration is vital for improving understanding, diagnosis, and care of psoriasis globally, ensuring better outcomes for patients.
What are the goals of the collaboration?
The collaboration aims to strengthen health policies, enhance knowledge, and improve access to care for those living with psoriasis.
How does psoriasis affect mental health?
Many individuals with psoriasis experience stigma, anxiety, and difficulty accessing opportunities due to their condition, which can impact their mental health.
What initiatives does IFPA support?
IFPA advocates for improved health systems, awareness campaigns, and supports global initiatives aimed at better treatment and care for psoriasis patients.
